Aldeyra Therapeutics acquires Helio Vision and with it ADX 2191, intravitreal methotrexate to treat proliferative vitreoretinopathy

Aldeyra Therapeutics, Inc. , a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that it has acquired Helio Vision, Inc. (Helio Vision), a privately held biotechnology company. The acquisition adds to Aldeyra's pipeline a Phase III-ready product candidate (ADX 2191, intravitreal methotrexate) for the treatment of proliferative vitreoretinopathy (PVR), a serious sight-threatening condition with no approved treatment. ADX 2191 has received Orphan Drug Designation from the U.S. Food and Drug Administration.